Brought to you by 
Taiho options rights to Arcus's immuno-oncology candidates; Options exercised
30 Nov 2021
Executive Summary
Arcus Biosciences Inc. granted Taiho Pharmaceutical Co. Ltd. an option to license exclusive rights in Asia (including Japan but excluding China) to develop and commercialize cancer immunotherapies from its pipeline.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Taiho options rights to Arcus's immuno-oncology candidates; Options exercised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice